Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, overvalued on P/F
Target Price
The average target price of XERS is 12 and suggests 68% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell